2019年β受体阻滞剂在慢性心衰中的作用(英文)-课件.pptVIP

下载本文档

0
0
约1.66万字
约 47页
2021-03-09 发布于广东
举报
版权申诉

2019年β受体阻滞剂在慢性心衰中的作用(英文)-课件.ppt

1、本文档共47页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

The Kaplan-Meier plot of death from any cause in the MERIT-HF trial showed that the benefit provided by metoprolol XL is seen very early, at approximately 3 months after initiation of treatment, and increases over time. There was a statistically significant decrease in total mortality in the metoprolol XL group compared with placebo. Relative risk reduction was 34%. Description:COPERNICUS = Carvedilol Prospective Randomized Cumulative Survival Trial; US-CARVEDILOL = U.S. Carvedilol heart failure study; CIBIS-II = Cardiac Insufficiency Bisoprolol Study II; MERIT-HF = Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure; CAPRICORN = Carvedilol Post-Infarct Survival Control in LV dysfunction Trial A Funnel Diagram Showing Use of Beta-Blocker Therapy in Patients with a History of Myocardial Infarction, Asymptomatic Left Ventricular Dysfunction, or Stable Heart Failure. For asymptomatic left ventricular dysfunction without coronary artery disease, beta-blockers are not currently recommended, but ongoing trials are deemed likely to show benefit. LVEF denotes left ventricular ejection fraction, and ACE angiotensin-converting enzyme. 2021/2/7 * MERIT-HF CIBIS-II 2021/2/7 * 2021/2/7 * Randomized (No run-in phase) COMET Study Design 3029 patients with stable heart failure, New York Heart Association Class II-IV, receiving standard treatment including ACE inhibitors Time to 1020 deaths Estimated to be 4 to 6 years Screening Titration to maximum tolerated or target dose (Start: carvedilol 3.125 mg bid, metoprolol tartrate 5 mg bid) Assessments every four months during maintenance phase (n?1500) Metoprolol 50 mg bid (n?1500) Carvedilol 25 mg bid Poole-Wilson PA et al. Eur J Heart Fail 2002;4:321-329. 2021/2/7 * Heart rate (beats.min-1) Metoprolol Carvedilol Time (years) 70 75 80 0 1 2 3 4 5 65 85 ** ** * COMET: Change of heart rate * p0.05, ** p0.01 Error bars represent 1 standard error 2021/2/7 * Time (years) Blood pressure (mm Hg) 70 80 90 100 11